Homology Medicines Announces Closing of Deal Leveraging its Internal Process Development and CMC Capabilities Through Newly Formed AAV Manufacturing Innovation Business with Oxford Biomedica
March 10, 2022 16:01 ET
|
Homology Medicines, Inc.
BEDFORD, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the successful closing of the deal with Oxford Biomedica plc...
Homology Medicines to Participate in Upcoming Investor Conferences
March 03, 2022 07:30 ET
|
Homology Medicines, Inc.
BEDFORD, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today participation at the following virtual investor conferences: ...
Homology Medicines Provides an Update on pheNIX Gene Therapy Trial for Adults with PKU
February 18, 2022 16:05 ET
|
Homology Medicines, Inc.
BEDFORD, Mass., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that the U.S. Food and Drug Administration (FDA) has notified...
Homology Medicines Announces Presentations on HMI-203 Investigational Gene Therapy for Hunter Syndrome and Broad Applicability of AAVHSC Platform for Lysosomal Storage Disorders at the 18th Annual WORLDSymposium™ Meeting
February 10, 2022 11:40 ET
|
Homology Medicines, Inc.
- Data Supported juMPStart Trial Evaluating One-Time, Systemic Administration of HMI-203 in ERT-Treated Adults - - Details of HMI-203 Clinical Trial Design and Encouraging Preclinical Data Featured...
Oxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines’ established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business in the U.S. with Homology Medicines as 20% owner
January 28, 2022 02:30 ET
|
Homology Medicines, Inc.
Oxford Biomedica and Homology Medicines to establish Oxford Biomedica Solutions LLC, a new U.S.-based AAV Manufacturing and Innovation Business Homology Medicines to receive $130 million from Oxford...
Homology Medicines Reports Third Quarter 2021 Financial Results and Recent Highlights
November 15, 2021 07:10 ET
|
Homology Medicines, Inc.
- Achieved Goal of Three Clinical Programs Across Gene Therapy and Gene Editing Technology Platform This Year - - Start of First Gene Editing Trial Advances Mission to Develop Solutions for Both...
Homology Medicines to Participate in Upcoming Investor Conferences
November 03, 2021 08:29 ET
|
Homology Medicines, Inc.
BEDFORD, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today participation in the following virtual...
Homology Medicines Announces Presentations Across Gene Therapy and Gene Editing Programs, including GTx-mAb, at European Society of Gene & Cell Therapy Meeting
October 21, 2021 07:00 ET
|
Homology Medicines, Inc.
- Data Support PKU and Hunter Syndrome Clinical Trials and PNH Program - BEDFORD, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company,...
Homology Medicines Announces Presentation of Data Supporting Clinical Programs in MPS II and PKU, including Nonclinical and Patient-Focused Research, at American Society of Human Genetics Meeting
October 20, 2021 08:30 ET
|
Homology Medicines, Inc.
- Oral Presentation on In Vivo Gene Therapy Product Candidate and Data on Gene Editing Candidate Paved Way for Initiation of juMPStart and pheEDIT Trials - BEDFORD, Mass., Oct. 20, 2021 (GLOBE...
Homology Medicines Initiates Clinical Trial for HMI-203, a One-Time Investigational Gene Therapy Candidate for Adults with MPS II (Hunter Syndrome)
October 18, 2021 08:30 ET
|
Homology Medicines, Inc.
- juMPStart Trial to Evaluate First Systemic Gene Therapy Candidate for Patients with Hunter Syndrome - BEDFORD, Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a...